Klein Lawrence Otto: insider trades.
Klein Lawrence Otto reported 5 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 4 sales ($7.1M), across 1 company.
- Transactions
- 5
- Purchases (P)
- 0
- Sales (S)
- 4
- Companies
- 1
- Name as filed
- Klein Lawrence Otto
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | Director, Officer · Chief Executive Officer | 5 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-15 | Oruka Therapeutics, Inc. | S | 2,452 | $95.71 | 923,128 | Form 4 |
| 2026-09-01 | Oruka Therapeutics, Inc. | S | 4,800 | $92.44 | 925,580 | Form 4 |
| 2026-09-01 | Oruka Therapeutics, Inc. | S | 63,596 | $91.9 | 930,380 | Form 4 |
| 2026-09-01 | Oruka Therapeutics, Inc. | M | 75,000 | $7.8 | 1,000,580 | Form 4 |
| 2026-09-01 | Oruka Therapeutics, Inc. | S | 6,604 | $90.79 | 993,976 | Form 4 |
Questions
What stock did Klein Lawrence Otto buy or sell?
Klein Lawrence Otto reported 5 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 4 sales ($7.1M), across 1 company.
Is Klein Lawrence Otto the same person as other filers with this name?
This page covers SEC CIK 1762583 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/klein-lawrence-otto-1762583.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.